Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.
Also called NCT05300672
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 207 participants
- Sponsor
- Registry
-
NCT05300672 -
2020-005242-41
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT05300672. Randomized; no masking; primary purpose treatment. Start 2022-02-08 (actual); primary completion 2024-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)
- Acronym
- FibER
- Condition
- Intracranial Hemorrhages
- Condition
- Ischemic Stroke
- Intervention (Drug)
- fibrinogen infusion
- Lead sponsor
- Azienda Usl di Bologna
- Collaborator
- Ministero della Salute, Italy
Record details
- Record id
cardio:ct-nct05300672- Content hash
c9ac5fd90761cfd8137214b20330a657b69fbd34dd8cb25337fddba34f30f80c